Melanoma Clinical Trials

Showing 1241-1260 of 1,292 trials

Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma

NCT01455103

The purpose of this study is to evaluate pharmacodynamic changes of BMS-936559 treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with unresectable Stage III or IV Melanoma.

Stage III or IV Melanoma

Bristol-Myers SquibbStarted Nov 2011

WITHDRAWNPhase 1

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

NCT00803374

The purpose of this study is to determine if BMS-663513 administered in combination with ipilimumab to patients with advanced malignant melanoma is safe and tolerable

Melanoma

Bristol-Myers SquibbStarted Nov 2010

Los Angeles, California, United States • New Haven, Connecticut, United States • Tampa, Florida, United States +4 more locations

TERMINATEDPhase 2/3

Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment

NCT00543205

This is an open-label, parallel-group study with a total of 16 evaluable subjects. Subjects will be assigned to 1 of the following cohorts: Cohorts I (subjects with normal hepatic function; n+8 and Cohort II (subjects with moderate hepatic impairment, Child-Pugh classification Grade B; n=8). If, for any reason, the Genasense infusion is interrupted or discontinued prior to completion or the rate of administration of the Genasense infusion is changed, the subject will be replaced.

Advanced Melanoma and Normal or ImpairedHepatic Function

Genta Incorporated6 participantsStarted Aug 2005

Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment

Related Searches

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

CP-461 in the Treatment of Patients With Advanced Melanoma

Study of XL281 in Adults With Solid Tumors

Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

Post-Operative Drainage Following Lymph Node Dissection

Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma

Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma

Phase II Trial of Allovectin-7® for Metastatic Melanoma

Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation

High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma

TNFerade™ Biologic Plus Radiation for Metastatic Melanoma

Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy

Differential Risks for Melanoma: p16 and DNA Repair

A Phase I/II Study of Sunitinib and Dacarbazine

Role of SLURP-1 in Melanoma and Melanoma Stem Cells

Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma

A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma